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Global, Regional, and National Cancer Incidence, Mortality,
Years of Life Lost, Years Lived With Disability, and Disability-
Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
A Systematic Analysis for the Global Burden of Disease Study
Global Burden of Disease Cancer Collaboration
IMPORTANCE Cancer is the second leading cause of death worldwide. Current estimates on
the burden of cancer are needed for cancer control planning.
OBJECTIVE To estimate mortality, incidence, years lived with disability (YLDs), years of life
lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and
territories from 1990 to 2015.
EVIDENCE REVIEW Cancer mortality was estimated using vital registration system data,
cancer registry incidence data (transformed to mortality estimates using separately
estimated mortality to incidence [MI] ratios), and verbal autopsy data. Cancer incidence was
calculated by dividing mortality estimates through the modeled MI ratios. To calculate cancer
prevalence, MI ratios were used to model survival. To calculate YLDs, prevalence estimates
were multiplied by disability weights. The YLLs were estimated by multiplying age-specific
cancer deaths by the reference life expectancy. DALYs were estimated as the sum of YLDs
and YLLs. A sociodemographic index (SDI) was created for each location based on income per
capita, educational attainment, and fertility. Countries were categorized by SDI quintiles to
summarize results.
FINDINGS In 2015, there were 17.5 million cancer cases worldwide and 8.7 million deaths.
Between 2005 and 2015, cancer cases increased by 33%, with population aging contributing
16%, population growth 13%, and changes in age-specific rates contributing 4%. For men, the
most common cancer globally was prostate cancer (1.6 million cases). Tracheal, bronchus, and
lung cancer was the leading cause of cancer deaths and DALYs in men (1.2 million deaths and
25.9 million DALYs). For women, the most common cancer was breast cancer (2.4 million
cases). Breast cancer was also the leading cause of cancer deaths and DALYs for women
(523 000 deaths and 15.1 million DALYs). Overall, cancer caused 208.3 million DALYs worldwide
in 2015 for both sexes combined. Between 2005 and 2015, age-standardized incidence rates
for all cancers combined increased in 174 of 195 countries or territories. Age-standardized
death rates (ASDRs) for all cancers combined decreased within that timeframe in 140 of 195
countries or territories. Countries with an increase in the ASDR due to all cancers were largely
located on the African continent. Of all cancers, deaths between 2005 and 2015 decreased
significantly for Hodgkin lymphoma (−6.1% [95% uncertainty interval (UI), −10.6% to −1.3%]).
The number of deaths also decreased for esophageal cancer, stomach cancer, and chronic
myeloid leukemia, although these results were not statistically significant.
CONCLUSION AND RELEVANCE As part of the epidemiological transition, cancer incidence is
expected to increase in the future, further straining limited health care resources.
Appropriate allocation of resources for cancer prevention, early diagnosis, and curative and
palliative care requires detailed knowledge of the local burden of cancer. The GBD 2015 study
results demonstrate that progress is possible in the war against cancer. However, the major
findings also highlight an unmet need for cancer prevention efforts, including tobacco
control, vaccination, and the promotion of physical activity and a healthy diet.
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I n 2015, cancer caused over 8.7 million deaths globally and wasthe second leading cause of death behind cardiovasculardiseases.1 Even though these impressive numbers are testi-
mony that the “war on cancer” has not been won, recent develop-
ments in personalized medicine and novel treatment approaches like
immunotherapy have raised hope of significantly improving cancer
survival.2-4 These expectations for patients with cancer in high-
income countries contrast with the challenge of making basic diag-
nostic and treatment options widely available in low-resource
settings.5 Both the equity and affordability of cancer care from in-
dividual and societal perspectives are increasingly being questioned.6
Survival rates between and within high-income countries differ for
reasons such as variation in education, access to specialized care,
effective treatment, and insurance status.7-9 The full potential of can-
cer prevention for reducing incidence and mortality is far from being
realized, and efforts are especially lagging in low-income countries.10
Awareness of this “cancer divide,” with substantially worse out-
comes and a high burden in socioeconomically disadvantaged popu-
lations, has led to a focus on global oncology by the international
health community.4,5,10 This is reflected in the third Sustainable
Development Goal (SDG) to “by 2030, reduce by one-third prema-
ture mortality from non-communicable diseases through preven-
tion and treatment and promote mental health and well-being.”11 Es-
timates of the burden of cancer are produced annually as part of the
Global Burden of Disease (GBD) study providing a unique means of
tracking progress in closing this divide. Here, we present results of
the GBD 2015 study for 32 cancer groups covering cancer inci-
dence, mortality, years of life lost (YLLs), years lived with disability
(YLDs), and disability-adjusted life years (DALYs) for 195 countries
or territories from 1990 to 2015 for both sexes across age groups.
Methods
Differences Between GBD 2015 and GBD 2013
General methods for GBD 2015 and prior GBD studies have been de-
scribed previously.1,12 Here, we present methods and results spe-
cific to the GBD 2015 cancer estimation. The general framework for
the cancer estimation in GBD 2015 has remained similar to GBD 2013,
exceptions are detailed below.13 The GBD 2015 study is compliant
with the newly developed Guidelines for Accurate and Transparent
Health Estimates Reporting (GATHER).14 A chart detailing fulfill-
ment of GATHER requirements is provided in eTable 1 in the Supple-
ment; flowcharts and a detailed description for each estimation step
are also available in the eAppendix and in the numerous eTables and
eFigures in the Supplement. Box 1 includes a list of the figures and
tables in this article. Further details about methods and data sources
are provided in the eAppendix, eFigures, and eTables in the Supple-
ment. Box 2 contains a list of the supplementary figures and tables.
Additional information is available from the authors in Web Tables 1
through 3; the web addresses for these items are listed in Box 3.
Hereinafter, citations to Web Tables are for those given in Box 3. Data
sources for GBD 2015 are listed in eTable 2 in the Supplement, in-
cluding which new sources were added compared with GBD 2013.
Relevant changes in the estimation strategy since GBD 2013
include the addition of 7 territories (American Samoa, Bermuda,
Greenland, Guam, Northern Mariana Islands, Puerto Rico, and the
US Virgin Islands), which previously were only included in the GBD
regional totals. Results for the United Kingdom are reported for
Northern Ireland, Scotland, Wales, and England). Changes to the GBD
causes include dividing “leukemia” into acute lymphoid leukemia,
chronic lymphoid leukemia, acute myeloid leukemia, and chronic my-
eloid leukemia. Methodological updates were made to the mortal-
ity to incidence (MI) ratio estimation, which are described in detail
in the eAppendix in the Supplement. Major updates for the MI ratio
predictions were out-of-sample validation of multiple model
types and selection of 1 model per cancer based on the out-of-
sample root-mean-squared error.
For GBD 2015, a sociodemographic index (SDI) was devel-
oped, which is a summary indicator derived from measures of
income per capita, educational attainment, and fertility. Detailed
methods describing computation of the SDI are reported elsewhere.1
In brief, the SDI weighs each component, which is rescaled be-
tween 0 and 1, equally. The composite SDI index is the mean of the
3 rescaled components. An SDI of 1.0 can be interpreted as a loca-
tion that has the highest observed educational attainment, the high-
est log income per capita, and the lowest fertility rate. For GBD 2015,
SDI quintiles were used to group countries that are similar based on
their development status. Locations were grouped into quintiles
based on their SDI value in 2015. Quintile cutoffs were based on the
distribution of geography-years from 1980 to 2015 with the excep-
tion of populations smaller than 1 million. eFigure 4 and eTable 8 in
the Supplement show the SDI quintile for each country. As for ev-
ery GBD study, the full time series estimated for each GBD cycle su-
persedes prior GBD studies. For GBD 2015, the full time series from
1990 to 2015 was estimated. We focus here on changes over the last
decade. Estimates before 2005 as well as additional results can be
found online (https://vizhub.healthdata.org/gbd-compare/).
Estimation Framework
The initial process in the burden of cancer estimation is the model-
ing of cancer mortality. One of the GBD study’s principles is to iden-
tify, and ideally use, all available data.15 Data inputs for cancer mor-
tality estimation therefore come from 2 major pathways: (1) mortality
data and (2) cancer registry incidence data transformed to mortal-
ity estimates. Mortality data from vital registration systems, verbal
autopsies, and other sources like disease surveillance records were
processed and added to a cause-of-death database. Methods and
data sources have been described in detail previously.1
Key Points
Question What is the burden of cancer between 1990 and 2015 at
the global, regional, and national level measured in incidence,
mortality, years lived with disability, years of life lost, and
disability-adjusted life-years (DALYs) by sex and age?
Findings Using the Global Burden of Disease (GBD) methodology,
we estimated that in 2015, there were 17.5 million cancer cases, 8.7
million deaths, and 208.3 million DALYs. Between 2005 and 2015,
incident cancer cases increased by 33%, of which 12.6% were due
to population growth, 16.4% due to an aging population, and 4.1 %
due to increasing age-specific incidence rates.
Meaning Cancer control, which requires a detailed understanding
of the cancer burden as provided in the GBD, is of utmost
importance given the rise in cancer incidence due to
epidemiological and demographic transition.
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To maximize data availability and take advantage of cancer reg-
istry data in countries with scarce mortality data, incidence data from
cancer registries were transformed to mortality estimates through the
use of separately estimated MI ratios. Modeling of the MI ratios is de-
scribed in detail in the eAppendix in the Supplement. In brief, the es-
timation followed a 3-step approach, the creation of logit random ef-
fect models, spatiotemporal smoothing, and Gaussian process
regression. A final model was selected based on out-of-sample vali-
dation. Updated cancer registry data for GBD 2015 was obtained from
the GBD collaborator network or downloaded from publically avail-
able sources. All data sources used for MI ratio estimation, as well as
those used for incidence data transformed to mortality estimates, are
listed in the eAppendix and eTable 2 in the Supplement.
For cancer estimation, 333 513 site-years were used from vital
registration systems, 785 site-years from verbal autopsy, 619 site
years from surveillance data, and 69 013 site years from cancer reg-
istry data. The number of site-years used by source type and by can-
cer can be found in eTable 3 in the Supplement. All data sources were
extracted at the most detailed cause- and age-specific level and
mapped to the GBD cause list. Codes from the International Classi-
fication of Diseases, Ninth Revision (ICD-9), and International Sta-
tistical Classification of Diseases and Related Health Problems, Tenth
Revision (ICD-10), for each GBD cancer group as well as a descrip-
tion of data processing steps can be found in the eAppendix in the
Supplement. The 32 cancer groups, together referred to as the “all
cancer” group, encompass all malignant neoplasms as defined in the
ICD-10 except for nonmelanoma skin cancer (NMSC, ICD-10 code
C44) and Kaposi sarcoma (ICD-10 code C46). Although NMSC is the
most common cancer in many populations, most cancer registries
do not include NMSC, which necessitates different estimation meth-
ods from the cancers presented here.16 Deaths due to Kaposi sar-
coma are not separately included because these were attributed to
human immunodeficiency virus/AIDS in the GBD study.
The combined data on individual causes of death were used as
input for the Cause of Death Ensemble model (CODEm).17 Covari-
ates used for each cancer are listed in the eAppendix in the Supple-
ment. Individual cause mortality estimates from CODEm were con-
strained to fit independently modeled, all-cause mortality estimates
using the tool CodCorrect.1 We calculated YLLs by multiplying each
death with the life expectancy for that age taken from a normative
life table; life expectancy at birth was 86.5 years, which is based on
the lowest observed death rate in each 5-year age group in popula-
tions over 5 million.1
Final mortality estimates were transformed into incidence es-
timates using modeled MI ratios. Uncertainty from the mortality es-
timation and from the MI ratio estimation was propagated to the
incidence estimates. Ten-year cancer prevalence was modeled by
estimating cancer survival using an MI ratio–based scaling factor,
which takes into account location, year, and sex (see the eAppen-
dix in the Supplement for details). This factor was used to scale the
incidence cohort between a theoretical best-case and a theoretical
worst-case survival. The absolute survival estimates allowed calcu-
lation of 10-year prevalence for each incidence cohort.
Total prevalence was divided into 4 sequelae reflecting vary-
ing degrees of disability during the cancer continuum: (1) diagnosis/
treatment, (2) remission, (3) metastatic/disseminated, and (4) ter-
minal phase. Duration of the 4 prevalence phases by cancer can be
found in eTable 13 in the Supplement. Since data sources including
stage distribution and treatment approaches are not available for
most countries, the simplifying assumption of a constant duration
of the diagnosis and treatment, metastatic/disseminated, and ter-
minal phase for all ages, over time, and all countries was made. Af-
ter dividing total prevalence into these 3 sequelae, we attributed the
remaining prevalence to the remission phase.
To calculate YLDs, the prevalence for each sequela was multi-
plied with a disability weight. Additional disability was estimated for
procedures and procedure-related morbidities associated with the
treatment of breast, larynx, colorectal, bladder, and prostate can-
cer (mastectomy, laryngectomy, stoma, urinary incontinence, and
impotence) under the assumption that these are major disabling
sequelae after cancer treatment. Disability weights used for the
different sequelae as well as methods to determine disability
prevalence for these cancer-related outcomes can be found in the
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We calculated 2 scenarios to analyze the contribution of
population aging, population growth, and changes in the age-
specific incidence rates on the absolute change of cancer incidence.
In the first scenario, the age structure, sex structure, and the age-
specific rates from 2005 were applied to the total population of the
year 2015. The difference between the total number of cases in 2005
and the hypothetical scenario were attributed to population growth.
In the second hypothetical scenario, the age-specific rates from 2005
were applied to the age structure, sex structure, and population size
of 2015. Differences between the second hypothetical scenario and
the first hypothetical scenario were attributed to population aging.
Differences between the total number of cases in 2015 and the sec-




standardized weights.18 We report 95% uncertainty intervals (UIs) for
all estimates (listed in parentheses after point estimates).
Results
Global Incidence, Mortality, and DALYs
In 2015, there were 17.5 million incident cancer cases worldwide and
8.7 million cancer deaths, as detailed in Table 1. Cancer caused 208.3
million DALYs in 2015, of which 96% came from YLLs and 4% came
from YLDs (Web Table 3). At the global level, the odds of develop-
ing cancer during a lifetime (age 0-79 years) differed between the
sexes: they were 1 in 3 for men and 1 in 4 for women (eTable 16 in
the Supplement). These odds differ substantially among SDI cat-
egories. In the lowest SDI quintile, the odds of developing cancer for
men aged between 0 and 79 years were 1 in 6, whereas in the high-
est SDI quintile, 1 in 2 men developed cancer. For women, the odds
of developing cancer was 1 in 5 in the lowest SDI quintile and 1 in 3
in the highest quintile.
In 2015, prostate cancer, TBL (tracheal, bronchus, and lung) can-
cer, and colorectal cancer were the most common incident (95% UI)
cancers in men—accounting for 42% of all cancer cases among men—
with 1.6 million (1.3-2.2 million), 1.4 million (1.3-1.5 million), and
920 000 (878 000-965 000) cases, respectively (Table 1). The
most common causes of cancer deaths for men were TBL, liver, and
stomach cancer with 1.21 (1.16-1.25) million, 577 000 (524 000-
622 000), and 535 000 (516 000-556 000) deaths, respectively.
The leading causes for cancer DALYs in 2015 for men were TBL, liver,
and stomach cancer, with 25.9 million (25.0-27.0 million), 15.4 mil-
lion (14.0-16.7 million), and 11.7 million (11.2-12.2 million), respec-
tively. For women in 2015, the most common incident cancers were
breast, colorectal, and TBL cancer, with 2.4 million (2.2-2.5 mil-
lion), 733 000 (702 000-767 000), and 640 000 (602 000-
690 000), respectively. These cancers were responsible for 46%
of all incident cases among women. The leading causes of cancer
deaths were breast, TBL, and colorectal cancer, 523 000 (492 000-
543 000), 517 000 (497 000-538 000), and 376 000 (363 000-
391 000) deaths, respectively. Breast, TBL, and colorectal cancer
were also the leading causes for female cancer DALYs in 2015, with
15.1 million (14.2-15.9 million), 10.5 million (10.1-11.0 million), and 7.2
million (7.0-7.5 million), respectively.
Figure 1 shows the pattern of cancer incidence and mortality by
age group. For childhood cancers (age 0-14 years), the most com-
mon were leukemia, other neoplasms (see eTables 4 and 5 in the
Supplement for ICD codes included under “other neoplasms”), non-
Hodgkin lymphoma (NHL), and brain and nervous system cancers
(Figure 1A). Leukemia, other neoplasms, and brain and nervous sys-
tem cancers were also the leading contributors to childhood can-
cer deaths (Figure 1B). For adolescents and young adults (age 15-39
years) the most common cancers at the global level were breast can-
cer, cervical cancer, and other neoplasms. The main causes of can-
cer deaths for this age group were leukemia, other neoplasms, and
liver cancer. For the population older than 39 years, the cancers con-
tributing the most incident cases were TBL, breast, prostate, and co-
lorectal cancer, while the main contributors to cancer deaths in this
age group were TBL, stomach, and colorectal cancer.
Between 2005 and 2015, age-standardized incidence rates
(ASIRs) for all cancers combined increased in 174 of 195 countries
or territories (Figure 2). China was a notable exception, with a 12%
decrease in cancer incidence. In contrast, age-standardized death
rates (ASDR) for all cancers combined decreased within that time-
frame in 140 of 195 countries or territories, as shown in Figure 3,
which also shows that countries with an increase in ASDR were largely
located on the African continent.
The number (95% UI) of incident cases increased in all SDI quin-
tiles between 2005 and 2015 for nearly all cancers; exceptions were
esophageal cancer in middle and high-middle SDI countries, where
incidence fell by 9% (−24.3% to 8.3%) and 4% (−17.7% to 14.0%),
respectively, and cervical cancer in middle, high-middle, and high SDI
countries, with a 5% (−19.6% to 12.3%), 5% (−14.3 to 6.2), and 2%
(−7.4% to 2.9%) decrease, respectively (Web Table 1). However, these
decreases were not statistically significant. The largest increase in
cancer incident cases between 2005 and 2015 occurred in low SDI
countries, with a 50% increase, of which population growth con-
tributed 33%, changing age-specific incidence rates 13%, and chang-
ing age structure 4% (eTable 15 in the Supplement). The second larg-
est increase occurred in the low-middle SDI quintile, with a 40%
increase, followed by high SDI countries, with a 36% increase, high-
middle SDI countries, with a 28% increase, and middle SDI coun-
tries, with a 27% increase (eTable 15 in the Supplement).
Global Top 10 Cancers in 2015
The top 10 cancers were ranked highest (top) number of incident
cases (Figure 4).
1. Breast Cancer
Breast cancer was the most common cancer overall, with an esti-
mated 2.4 million (95% UI, 2.3-2.5 million) incident cases in 2015.
The vast majority occurred in women, with 2.4 million (95% UI, 2.2-
2.5 million) cases vs 44 000 (95% UI, 40 000-49 000) cases in men
Box 3. Web Table Addresses
Web Table 1. Incidence (absolute numbers and rates) by sex, 2005,
2015 (ja.ma/healthdataorg_webtable1_incidence)
Web Table 2. Mortality (absolute numbers and rates) by sex, 2005,
2015 (ja.ma/healthdataorg_webtable2_mortality)
Web Table 3. DALYs (absolute numbers and rates) by sex, 2005,
2015 (ja.ma/healthdataorg_webtable3_DALYs)
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(Table 1). Breast cancer was the leading cause of cancer in all SDI quin-
tiles except for the high and high-middle SDI quintiles where it was
the second most common cancer (Figure 4). It was the cause of death
for 523 000 (95% UI, 492 000-543 000) women and 10 000 (95%
UI, 9000-11 000) men, making it the fifth leading cause of cancer
deaths for both sexes in 2015 at the global and the low SDI coun-
tries, the fourth leading cause in high SDI countries, the sixth lead-
ing cause in high-middle and middle SDI countries, and the third lead-
ing cause in the low-middle SDI quintile (Figure 5). For women, breast
cancer was the leading cause of death in 2015 (Table 1). Breast can-
cer caused 15.4 million (95% UI, 14.4-16.2 million) DALYs for both
sexes, of which 88% came from YLLs, and 12% from YLDs (eFigure
13 in the Supplement). One in 14 women and 1 in 603 men devel-
oped breast cancer between birth and age 79 years (eTable 16 in the
Supplement) at the global level. For women, the odds of develop-
ing breast cancer were the highest in high SDI countries, with 1 in 9
women developing breast cancer, compared with the lowest odds
of 1 in 20 women in middle SDI countries developing breast cancer
between age 0 and 79 years.
For women (per 100 000 person-years) in 2015, ASIRs (95%
UIs) and ASDRs (95% UIs) were the lowest in East Asia: ASIR 35.8
(27.5-45.4), ASDR 8.2 (6.9-9.3); South Asia: ASIR 44.4 (37.1-52.3),
ASDR 11.9 (10.6-12.9); and Andean Latin America: ASIR 47.2 (39.6-
54.6), ASDR 10.5 (9.1-12) (Web Tables 1 and 2). They were the high-
est in high-income North America: ASIR 124.8 (115.9-145.4), ASDR
19.9 (18.9-23.2); Western Europe: ASIR 124.7 (116.3-138.3), ASDR 21.8
(20.5-23.6); and Australasia: ASIR 123.7 (112.5-137.9), ASDR 19.8 (18.3-
21.4).
Figure 1. Age-Specific Global Contributions of Cancer Types to Total Cancer Incidence and Mortality For Both Sexes, 2015
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Breast cancer was the most common cancer for women in 183
countries or territories and the most common cause of cancer deaths
in women in 115 countries or territories (eFigures 10 and 12 in the
Supplement).
Between 2005 and 2015, breast cancer remained the fifth lead-
ing cause of global cancer YLLs, as shown in Figure 6. If global popu-
lation size and age structure had remained stable between 2005 and
2015, the change in age-specific incidence rates between 2005 and
2015 would have resulted in a 15% increase in incident cases (Table 2).
Overall incident cases increased by 43% because of population
growth (contributing an additional 13%) and aging (contributing
15%). The ASIR (95% UI) for women (per 100 000 person-years) be-
tween 2005 and 2015 increased by 12% (95% UI, 4.3%-19.5%) at
the global level from 58.5 (55.7-61.9) to 65.5 (61.7-68.8). The larg-
est increase occurred in low SDI countries, with a 26% increase, from
52.8 (43.8-70.2) to 66.4 (51.3-88.2). ASIR at the global level and for
all SDI quintiles increased since 1990 (Figure 7). Age-standardized
DALY rates (95% UI) for women between 2005 and 2015 de-
creased by 6% (−12.1% to −1.0%) at the global level, with the larg-
est decrease of 10% (−17.9% to −3.3%) in high-middle SDI coun-
tries and the largest increase in low SDI countries of 10% (−12.5%
to 38.5%), which was not statistically significant (Web Table 3).
2. Tracheal, Bronchus, and Lung Cancer
In 2015, there were 2 million (95% UI, 1.9-2.1 million) incident cases
of TBL cancer and 1.7 million (95% UI, 1.67-1.77 million) deaths. Tra-
cheal, bronchus, and lung cancer caused 36.4 million (95% UI, 35.4-
37.6 million) DALYs in 2015, of which 99% came from YLLs and 1%
from YLDs (eFigure 13 in the Supplement). Men were more likely to
develop TBL cancer than women, with 1 in 18 men and 1 in 45 women
developing TBL cancer between birth and age 79 years (eTable 16 in
the Supplement). The odds were the highest in high SDI countries, with
1 in 13 men and 1 in 27 women developing TBL cancer. In low SDI coun-
tries the odds were substantially lower, with 1 in 70 men and 1 in 199
women developing TBL cancer between birth and age 79 years. Over-
all, TBL cancer had the second highest absolute incidence globally as
well as in middle and low-middle SDI countries; TBL was the leading
cause of cancer in high-middle SDI countries and ranked fourth in high
SDI countries and tenth in low SDI countries (Figure 4). It was the most
common cause of cancer deaths by absolute cases globally as well as
in all SDI quintiles except for countries in the low SDI group, where
TBL cancer ranked seventh (Figure 5).
ASIRs and ASDRs (95% UI) (per 100 000 person-years) for men
were the lowest in Eastern Sub-Saharan Africa: ASIR 8.6 (6.9-10.7),
ASDR 10.3 (8.1-13.0); Central Sub-Saharan Africa: ASIR 11.7 (7.8-17.0),
ASDR 14.2 (9.3-20.9); and Western Sub-Saharan Africa: ASIR 12.8 (10.7-
16.5), ASDR 13.9 (11.4-17.4). They were the highest in men in high-
income North America: ASIR 70.9 (66.3-75.7), ASDR 50.3 (48.3-
52.3); Central Europe: ASIR 70.5 (66.5-75.0), ASDR 61 (58.6-63.1); and
high-income Asia Pacific: ASIR 67.5 (62.8-72.4), ASDR 42.1 (40.5-
43.8). For women in 2015, incidence rates were the lowest in East-
ern Sub-Saharan Africa: ASIR 2.7 (2.0-3.6), ASDR 3.2 (2.3-4.2);
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Data reflect both sexes for all cancers excluding nonmelanoma skin cancer in
195 countries or territories from 2005 to 2015. The 95% UIs are reported in
Web Table 1. ATG indicates Antigua and Barbuda; BRB, Barbados;
COM, Comoros; DMA, Dominica; E Med: Eastern Mediterranean; FJI, Fiji;
FSM, Federated States of Micronesia; GRD, Grenada; KIR, Kiribati; KS, Kaposi
sarcoma; LCA, Saint Lucia; MDV, Maldives; MLT, Malta; MUS, Mauritius;
MHL, Marshall Islands; NMSC, nonmelanoma skin cancer; SGP, Singapore;
SLB, Solomon Islands; SYC, Seychelles; TLS, Timor-Leste; TON, Tonga;
TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines;
VUT, Vanuatu; W Africa, West Africa; WSM, Samoa.
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Western Sub-Saharan Africa: ASIR 5.2 (3.9-7.5), ASDR 5.6 (4.3-8.1); and
South Asia: ASIR 5.3 (4.5-6.3), ASDR 5.5 (5.1-5.9). Incidence rates were
the highest in high-income North America: ASIR 51.7 (48.2-55.5), ASDR
32.9 (31.6-34.1); Australasia: ASIR 28.9 (25.7-32.4), ASDR 19.3 (18.0-
20.8); and high-income Asia Pacific: ASIR 25.4 (23.5-27.5), ASDR 12.6
(12.0-13.2). (Web Tables 1 and 2). Tracheal, bronchus, and lung can-
cer was the cause of the most incident cases for men in 38 countries
and the most common cause for cancer deaths in 113 countries or ter-
ritories (eFigures 9 and 11 in the Supplement). For women, TBL can-
cer was the most common cause of cancer deaths in 20 countries and
territories (eFigure 12 in the Supplement).
Between 2005 and 2015, TBL cancer cases increased by 29%
(95% UI, 21.5%-37.0%) (Web Table 1). Population growth alone con-
tributed 13%. Aging of the population contributed 18% of the total
increase. This increase was partially offset by a decrease in age-
specific rates, which would have led to a 2% decrease in incidence
if the age structure and population size had remained constant be-
tween 2005 and 2015. Figure 8 shows slightly decreasing ASIR at
the global level for men and increasing trends for women between
1990 and 2015. This trend was much more pronounced for the high
SDI quintile.
3. Colon and Rectum Cancer
In 2015, there were 1.7 million (95% UI, 1.6-1.7 million) incident cases
of colon and rectum cancer, and it caused 832 000 (95% UI,
812 000-855 000) deaths (Table 1). Colon and rectum cancer caused
17 million (95% UI, 16.6-17.5 million) DALYs in 2015 of which 96%
came from YLLs and 4% came from YLDs (eFigure 13 in the Supple-
ment). The odds of developing colon and rectum cancer before age
79 years at the global level was higher for men than for women (1 in
28 men, 1 in 43 women, eTable 16 in the Supplement). The highest
odds were in the high SDI quintile, with 1 in 14 men and 1 in 23 women
developing colorectal cancer compared with 1 in 94 men and 1 in 112
women in the low SDI quintile. Globally, and for high SDI countries,
colon and rectum cancer ranked third for cancer incidence and sec-
ond for cancer deaths in 2015 as shown in Figures 4 and 5. Colon and
rectum cancer incidence ranked lowest in low SDI countries as the
eighth most common cancer and was the sixth leading cause for can-
cer mortality.
As can be seen in Web Tables 1 and 2, in 2015 ASIRs and ASDRs
(95% UI) per 100 000 person-years for men were the lowest in
South Asia: ASIR 8.2 (6.9-9.5), ASDR 6.3 (5.8-6.8); Central Sub-
Saharan Africa: ASIR 8.7 (5.9-12.9), ASDR 9.5 (6.4-14.1); and West-
ern Sub-Saharan Africa: ASIR 9.0 (7.4-12.2), ASDR 8.7 (7.2-11.1). Rates
were highest in Australasia: ASIR 86.4 (76.1-98.5), ASDR 21.3 (19.9-
22.9); high-income Asia Pacific: ASIR 78.7 (74.3-83.4), ASDR 21.8
(21.1-22.6); and Western Europe: ASIR 60.0 (56.7-63.3), ASDR 21.9
(20.9-22.8). For women, rates in 2015 were the lowest in Western
Sub-Saharan Africa: ASIR 7.1 (5.6-9.8), ASDR 7.1 (5.6-10.1); South Asia:
ASIR 7.1 (6.0-8.4), ASDR 5.7 (5.3-6.2); and Central Sub-Saharan Africa:
ASIR 8.3 (5.3-12.3), ASDR 9.1 (5.5-14.0). They were the highest in Aus-
tralasia: ASIR 64.9 (56.6-74.5), ASDR 15.3 (14.1-16.7); high-income Asia
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Data reflect both sexes for all cancers excluding nonmelanoma skin cancer in
195 countries or territories from 2005 to 2015. The 95% UIs are reported in
Web Table 2. ATG indicates Antigua and Barbuda; BRB, Barbados;
COM, Comoros; DMA, Dominica; E Med: Eastern Mediterranean; FJI, Fiji;
FSM, Federated States of Micronesia; GRD, Grenada; KIR, Kiribati; KS, Kaposi
sarcoma; LCA, Saint Lucia; MDV, Maldives; MLT, Malta; MUS, Mauritius;
MHL, Marshall Islands; NMSC, nonmelanoma skin cancer; SGP, Singapore;
SLB, Solomon Islands; SYC, Seychelles; TLS, Timor-Leste; TON, Tonga;
TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines;
VUT, Vanuatu; W Africa, West Africa; WSM, Samoa.
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Pacific: ASIR 43.7 (40.9-46.8), ASDR 12.7 (12.2-13.3); and high-
income North America: ASIR 42.8 (39.6-46.4), ASDR 13.4 (12.8-
14.0). Colon and rectum cancer was the cancer with the highest in-
cidence in 2015 for men in 6 countries (eFigure 9 in the Supplement).





















































































































































































































































































































































































Global 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
2 4 3 1 5 10 6 13 8 22 15 11 12 7 18 9 14 17 16 24 21 23 20 25 30 19 31 27 26 28 29
2 1 4 5 3 6 9 7 10 11 8 12 13 16 15 20 18 14 19 17 23 24 21 26 22 27 25 28 29 30 31
1 2 5 9 3 4 10 8 12 7 6 13 15 23 11 26 17 14 20 16 21 22 25 24 18 27 19 28 30 29 31
1 2 7 10 3 9 8 6 12 4 11 18 17 23 5 26 21 14 20 13 25 19 24 15 16 28 22 27 30 29 31
1 10 8 7 3 4 5 6 13 2 9 20 15 23 11 21 19 16 18 17 27 14 24 22 12 25 26 29 30 28 31
1 3 5 10 4 14 8 6 12 7 9 19 16 28 2 27 22 15 18 11 23 17 24 13 20 25 21 26 30 29 31
1 4 6 10 3 14 8 7 13 5 9 20 15 28 2 25 22 16 18 11 23 17 24 12 19 26 21 27 30 29 31
1 3 5 16 9 13 4 6 8 17 7 11 20 22 2 29 21 12 14 10 27 19 25 15 18 23 24 28 26 30 31
1 2 4 12 7 11 8 6 14 5 10 22 18 29 3 26 21 17 20 9 23 16 25 13 15 28 19 24 30 27 31
1 5 9 15 3 11 8 4 16 2 12 22 17 29 6 27 19 18 20 7 23 14 25 10 13 28 21 24 30 26 31
4 1 5 12 2 3 8 7 9 11 6 10 14 19 15 24 20 13 22 17 18 25 23 27 21 26 16 28 31 29 30
4 1 5 12 2 3 8 7 9 11 6 10 14 20 15 24 19 13 23 17 18 25 22 27 21 26 16 28 31 29 30
1 2 3 9 7 4 8 6 15 5 20 13 16 19 10 26 12 17 14 21 25 23 24 22 11 29 18 27 30 28 31
1 9 7 5 4 8 6 3 13 2 20 10 16 21 15 26 14 17 12 19 24 22 25 23 11 29 18 27 31 28 30
1 2 3 6 11 7 10 4 21 5 25 12 19 20 9 22 8 16 15 18 24 14 27 26 13 28 17 29 30 23 31
2 1 3 10 4 5 6 8 17 11 12 16 14 22 7 27 15 20 13 21 29 23 24 9 19 28 18 26 25 30 31
2 1 4 8 9 3 11 5 14 7 18 21 17 13 10 28 15 16 20 19 25 23 12 22 6 29 24 27 30 26 31
1 3 5 14 4 8 9 6 16 2 25 12 15 24 7 26 11 17 13 21 23 20 22 19 10 29 18 27 30 28 31
1 2 3 6 7 9 5 4 15 8 20 16 17 19 13 24 12 21 14 18 23 22 28 25 11 26 10 29 30 27 31
1 2 5 6 3 10 8 4 7 11 22 18 14 20 19 24 16 9 21 17 13 12 23 29 15 27 28 26 30 25 31
1 5 7 9 8 4 13 2 3 18 23 17 16 20 14 26 15 6 21 19 10 12 24 25 11 27 30 29 31 22 28
2 5 6 3 1 14 12 4 7 17 9 25 19 21 23 16 20 8 24 10 13 11 22 30 15 27 28 26 29 18 31
2 1 4 5 3 14 7 6 8 21 26 13 10 17 22 19 15 9 18 16 12 11 24 31 20 23 28 27 25 29 30
1 4 6 12 2 7 5 3 14 8 19 23 15 25 16 27 13 9 24 18 17 11 22 26 10 29 28 21 30 20 31
1 2 4 8 5 15 7 3 9 6 28 20 14 25 23 26 18 10 22 19 17 13 11 29 16 24 12 21 31 27 30
1 3 8 18 6 11 10 2 7 14 25 17 15 19 16 24 13 4 20 22 12 5 26 23 9 27 28 29 30 21 31
1 2 7 5 3 10 9 4 8 6 27 12 14 25 15 24 17 11 21 18 16 13 19 23 20 26 22 29 31 28 30
1 5 8 17 2 6 7 4 12 3 15 19 23 28 20 27 10 9 25 21 18 14 16 24 11 29 26 13 31 22 30
1 4 2 6 8 7 5 3 10 20 23 15 12 11 17 28 13 9 19 16 18 14 25 29 21 24 26 27 30 22 31
1 4 7 14 2 8 6 3 13 5 20 23 17 28 16 26 12 9 24 21 15 11 22 25 10 29 27 18 31 19 30
2 4 3 1 9 12 6 10 5 22 18 13 11 7 17 8 14 15 16 25 19 24 21 23 31 20 30 29 26 28 27
1 4 3 2 7 13 6 11 9 23 20 12 10 8 18 5 15 16 14 25 21 24 19 22 30 17 31 29 26 28 27
2 4 3 1 10 12 5 8 9 24 15 16 13 6 14 7 11 18 20 22 17 23 25 19 31 21 28 29 26 27 30
1 3 2 4 9 15 7 8 11 23 12 13 10 5 19 6 22 17 14 26 16 20 24 25 31 18 30 28 27 29 21
2 4 3 1 6 8 7 12 5 22 24 13 11 10 20 14 9 15 18 21 17 23 19 25 31 16 30 29 27 26 28
1 4 2 3 9 15 7 8 11 23 12 13 10 5 19 6 22 17 14 27 16 20 24 25 31 18 30 29 26 28 21
3 4 2 1 7 9 8 10 5 20 24 12 13 6 15 11 16 14 17 19 18 25 22 23 30 21 29 28 27 26 31
1 8 9 6 3 4 5 7 10 2 17 20 11 15 16 21 23 14 22 18 27 12 19 24 13 25 29 26 30 28 31
1 8 9 6 3 5 2 7 12 4 17 22 11 10 16 21 24 15 20 18 26 13 19 23 14 25 29 27 30 28 31
1 12 8 4 6 5 2 7 10 3 19 16 9 17 14 24 25 11 20 18 26 15 23 21 13 22 29 28 30 27 31
1 11 9 7 4 5 3 8 13 2 6 19 16 25 10 21 20 15 14 18 27 17 26 24 12 23 22 30 29 28 31
1 11 6 8 4 3 5 7 15 2 9 19 14 26 10 21 18 17 13 20 27 16 25 23 12 24 22 30 29 28 31
1 10 8 6 7 4 3 5 14 2 9 21 17 23 12 20 19 13 15 18 27 16 26 25 11 22 24 29 31 28 30
2 17 8 4 3 7 6 5 19 1 10 20 14 26 9 24 22 13 12 11 27 16 23 25 15 21 18 30 29 28 31
1 10 6 4 9 7 3 8 17 2 5 18 15 22 13 21 20 14 11 23 27 16 26 25 12 24 19 30 29 28 31
1 9 7 12 4 3 8 5 15 2 6 20 17 24 10 22 19 14 16 18 26 13 25 21 11 23 28 29 31 27 30
2 3 4 1 13 14 5 11 7 22 21 10 12 9 15 6 8 17 19 23 18 20 26 24 29 16 31 27 25 30 28
2 3 4 1 14 13 5 11 7 23 21 9 12 10 15 6 8 17 19 22 18 20 26 24 30 16 31 27 25 29 28
2 4 3 1 7 17 5 10 9 23 21 11 12 6 20 8 13 14 18 24 16 19 22 25 29 15 31 27 26 30 28
1 6 5 2 3 9 8 7 16 4 25 15 12 10 19 18 13 17 14 22 23 21 20 29 11 26 30 27 24 28 31
1 7 4 2 5 9 8 6 16 3 27 15 14 10 21 18 11 17 12 24 23 22 19 29 13 26 30 25 20 28 31
1 4 5 3 2 9 6 8 17 7 24 18 10 20 16 13 11 12 14 21 22 23 19 29 15 25 30 27 28 26 31
1 4 5 2 6 14 7 8 11 3 26 9 12 10 16 20 17 18 13 15 23 21 22 29 19 25 30 24 28 27 31
2 3 1 5 4 15 12 10 9 14 19 6 8 7 17 13 24 16 11 18 20 26 22 21 29 23 30 25 27 28 31
2 3 1 6 5 14 9 10 11 15 19 4 8 7 17 12 24 16 13 20 18 26 25 23 28 22 30 21 27 29 31
3 2 1 5 4 17 18 12 8 11 19 6 7 10 14 13 23 16 9 15 30 22 20 21 28 24 31 27 29 26 25
1 4 3 2 5 16 7 8 10 6 11 18 13 19 9 14 17 12 21 15 25 22 23 20 26 24 30 27 29 28 31
1 4 3 2 5 16 7 9 10 6 11 18 13 19 8 14 17 12 21 15 25 22 23 20 26 24 30 27 29 28 31
5 3 1 4 2 6 9 14 13 16 12 15 7 8 18 28 10 20 17 23 25 19 11 22 24 21 30 31 27 26 29
5 3 1 4 2 6 9 14 12 18 11 15 7 8 16 29 13 20 17 23 27 19 10 22 24 21 30 31 25 28 26
5 3 2 7 1 4 10 12 13 14 15 16 8 11 19 27 6 18 17 22 25 20 9 24 23 21 28 29 30 26 31
3 1 2 4 6 15 11 10 5 14 23 8 9 7 17 12 25 13 16 18 19 26 21 20 29 24 30 27 22 28 31
2 1 3 4 8 20 13 11 5 14 21 7 9 6 17 15 24 12 10 16 18 26 19 22 29 23 31 27 25 28 30
1 6 7 9 4 3 8 5 15 2 10 21 14 22 11 20 19 17 18 12 25 16 24 23 13 26 27 28 30 29 31
1 6 8 10 3 4 7 5 16 2 9 20 14 25 11 21 18 17 19 12 24 15 23 22 13 26 27 28 30 29 31
1 3 4 7 2 9 13 6 11 5 10 8 16 17 14 19 23 12 18 15 22 20 24 25 21 29 30 26 27 28 31
1 3 6 11 2 13 8 4 14 5 7 15 20 18 12 19 26 9 22 10 21 16 24 25 17 30 27 23 29 28 31
1 4 5 2 7 9 12 8 11 3 6 16 13 22 10 14 20 21 17 15 23 19 25 26 18 24 28 27 31 30 29
1 4 5 2 7 14 13 8 10 3 6 16 12 21 9 11 18 22 17 15 24 19 25 26 20 23 28 27 31 30 29
1 4 3 2 5 17 13 11 10 6 15 14 8 9 19 16 12 20 18 22 23 21 7 29 26 25 31 28 24 27 30
1 4 3 2 5 18 12 11 8 6 15 13 7 9 17 16 10 21 19 20 23 22 14 29 26 25 31 28 24 27 30
1 7 5 3 2 10 6 8 15 4 24 9 13 16 21 20 12 14 19 22 25 18 11 26 17 23 30 29 28 27 31
1 6 5 2 3 9 7 8 16 4 25 10 11 15 21 19 12 14 17 22 23 20 13 26 18 24 30 29 27 28 31
2 4 3 1 6 11 8 9 10 5 16 7 14 15 12 22 18 17 19 13 21 23 25 24 26 20 29 27 30 28 31
3 5 2 1 8 15 6 10 12 25 17 9 11 7 23 4 13 14 18 26 19 20 22 21 28 16 31 30 27 29 24
1 4 7 10 3 6 9 5 18 2 24 8 16 28 11 22 13 23 20 15 29 12 25 14 21 27 19 26 30 17 31
Country
China
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For women, colon and rectum cancer was the most common cause
of cancer deaths in 5 countries (eFigure 12 in the Supplement).
Colon and rectum cancer has remained the fourth leading cause
for cancer YLLs between 2005 and 2015 (Figure 6). As summarized





















































































































































































































































































































































































Global 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
1 2 3 6 4 10 5 7 8 18 9 14 11 13 15 20 16 12 26 23 17 21 24 29 22 19 27 25 28 30 31
1 4 3 2 6 5 7 8 9 11 12 10 13 15 16 18 14 19 17 20 21 22 24 23 25 26 27 29 28 30 31
1 4 3 2 6 5 8 10 7 9 12 11 15 17 16 14 19 22 13 20 23 21 24 18 25 28 27 30 26 29 31
1 5 2 4 3 6 11 10 8 7 12 13 15 16 18 9 20 23 17 14 22 19 21 24 26 29 25 31 28 27 30
7 6 3 1 5 4 10 8 9 2 11 12 13 14 17 18 19 21 16 22 20 15 23 25 26 27 24 31 29 28 30
1 3 5 8 2 4 10 13 7 9 11 14 15 16 17 6 20 24 19 12 21 22 18 23 27 29 25 31 28 26 30
1 4 2 8 5 3 10 11 7 6 13 14 16 15 17 9 20 24 19 12 21 23 18 22 27 29 25 31 28 26 30
2 4 9 6 1 3 14 15 8 19 7 10 12 16 20 5 23 22 18 11 17 13 21 24 28 30 25 31 29 27 26
1 2 5 9 4 7 10 12 6 8 13 11 17 18 15 3 21 26 16 14 23 22 19 20 27 30 24 31 28 25 29
1 6 2 7 3 8 9 13 5 4 12 11 18 16 15 14 20 27 17 10 23 21 19 22 26 29 24 31 28 25 30
1 5 3 2 7 4 6 10 8 12 11 9 15 20 18 17 16 21 13 19 23 22 27 14 24 26 30 28 25 29 31
1 5 3 2 7 4 6 10 8 12 11 9 15 20 18 17 16 21 13 19 23 22 28 14 24 26 30 27 25 29 31
1 3 5 2 4 11 8 10 6 7 12 14 18 13 17 15 16 20 9 22 25 21 23 19 30 29 26 28 24 27 31
5 6 3 2 1 12 8 9 4 7 11 14 16 13 15 22 18 20 10 21 24 19 23 17 30 28 26 29 25 27 31
1 3 8 4 2 20 10 6 5 7 13 12 22 14 11 15 24 19 9 21 25 17 26 16 29 27 23 28 18 30 31
1 3 4 2 5 6 7 12 8 11 9 16 17 13 20 10 19 22 15 21 24 23 14 18 31 29 27 28 25 26 30
2 3 7 1 5 13 10 12 4 9 18 14 16 17 21 11 8 15 6 19 25 24 22 20 30 29 28 26 23 27 31
1 3 4 6 2 16 8 13 7 5 12 14 18 10 19 11 17 22 9 21 25 15 23 20 28 29 26 30 24 27 31
1 2 6 4 3 14 9 11 5 12 8 16 17 13 18 15 23 19 7 21 20 24 25 10 29 27 26 30 22 28 31
1 4 2 6 3 13 9 8 5 15 12 7 11 17 10 24 16 19 14 18 21 20 30 25 22 29 23 28 27 26 31
2 6 8 1 4 15 10 12 3 19 13 5 7 16 11 22 21 18 9 17 24 20 27 29 14 28 23 25 26 30 31
2 5 1 9 7 4 11 8 3 20 16 6 14 19 10 22 15 18 13 12 23 26 29 27 21 24 17 30 28 25 31
1 2 3 9 6 18 5 7 4 22 11 8 12 13 10 25 19 16 17 15 14 20 31 26 21 24 27 23 28 29 30
2 6 1 4 3 13 10 8 5 14 9 7 15 17 11 22 16 21 12 19 23 18 28 27 24 30 20 29 26 25 31
1 2 5 9 3 20 6 8 4 10 12 7 14 18 13 25 11 21 15 19 17 22 28 16 23 30 24 29 27 26 31
1 7 8 5 2 17 9 13 3 18 12 4 11 15 6 20 23 14 10 22 24 16 26 27 21 28 19 29 25 30 31
1 4 3 7 2 17 9 5 6 10 12 8 11 16 14 23 15 22 18 19 20 13 26 24 21 30 25 27 29 28 31
3 5 1 4 2 9 15 11 6 7 10 8 14 20 17 24 12 23 16 18 25 13 28 27 22 30 21 29 26 19 31
2 1 7 3 4 12 8 10 5 21 9 6 15 16 11 22 18 13 14 20 17 24 27 23 25 29 19 30 26 28 31
1 6 2 4 3 13 9 11 5 10 8 7 15 18 14 24 16 22 12 19 25 17 27 28 23 30 20 29 26 21 31
1 2 6 8 3 11 5 4 7 21 10 13 9 12 15 20 17 14 27 24 16 23 25 29 18 19 26 22 28 30 31
1 2 6 8 3 14 4 5 7 22 10 13 9 12 15 20 16 11 28 25 17 23 21 29 18 19 26 24 27 30 31
1 2 8 6 3 10 4 5 7 22 11 15 9 12 16 19 18 14 27 23 13 24 20 28 17 21 26 25 29 30 31
1 2 8 12 3 6 5 4 7 23 10 13 9 11 14 22 20 15 28 26 16 21 25 27 19 18 24 17 29 30 31
1 2 4 6 3 18 5 7 8 23 10 12 9 14 15 19 13 11 27 21 16 24 26 29 17 20 25 22 28 30 31
1 2 8 12 3 6 5 4 7 23 10 13 9 11 14 22 20 15 28 25 17 21 26 27 19 18 24 16 29 30 31
1 2 5 8 3 15 6 4 9 23 10 11 7 12 13 19 17 14 27 20 16 21 24 28 18 22 25 26 29 30 31
4 7 2 1 6 11 9 5 8 3 10 12 13 18 14 21 17 15 16 22 20 19 23 30 27 26 24 31 29 25 28
3 6 2 1 7 11 9 5 8 4 10 12 16 19 14 21 17 13 15 22 18 20 23 28 27 25 24 31 29 26 30
8 10 4 1 2 13 6 3 9 5 7 11 14 18 15 20 19 21 12 22 17 16 23 29 25 26 24 30 28 27 31
8 4 6 2 5 3 11 7 9 1 10 13 14 12 18 17 22 21 16 20 19 15 24 23 28 25 27 30 26 31 29
8 3 6 2 5 4 11 7 9 1 10 13 16 12 18 14 20 22 17 21 19 15 24 23 27 26 28 30 25 31 29
8 3 7 2 5 4 11 6 9 1 10 13 14 12 16 19 22 20 15 21 18 17 24 23 28 25 27 29 26 31 30
11 4 2 3 5 7 9 6 8 1 13 12 20 10 16 18 21 23 17 14 15 19 24 22 25 28 26 30 27 31 29
6 2 8 4 9 1 12 3 10 5 7 13 17 11 19 20 23 18 16 22 15 14 24 21 28 25 27 30 26 31 29
7 5 4 1 6 3 12 9 8 2 10 11 15 14 16 17 22 21 13 20 19 18 23 28 25 26 24 29 27 30 31
1 2 9 8 3 10 4 5 6 20 7 13 11 14 12 21 22 15 26 23 16 19 25 30 18 17 27 24 28 29 31
1 2 14 8 3 9 4 5 6 20 7 12 11 13 10 21 23 15 26 22 16 19 25 30 18 17 27 24 28 29 31
1 2 6 12 3 10 5 4 8 20 7 11 9 13 15 21 17 14 27 24 16 23 25 29 18 19 26 22 28 30 31
1 3 2 6 5 17 9 4 7 8 10 12 18 13 16 22 14 15 11 20 19 21 28 30 26 23 25 31 24 27 29
1 4 2 6 5 18 9 3 7 8 10 13 17 14 16 21 15 12 11 20 19 22 30 31 27 24 26 29 23 25 28
2 3 1 7 4 15 9 5 6 8 10 11 17 14 16 21 13 19 12 20 18 22 28 29 26 23 24 30 25 27 31
1 4 3 9 5 17 8 2 7 6 10 11 18 12 16 22 19 13 14 15 20 21 27 29 26 24 23 31 28 25 30
1 2 3 8 4 13 5 6 9 14 18 12 11 7 20 15 22 10 25 17 23 16 21 30 24 19 26 28 27 29 31
1 2 3 7 4 12 5 6 10 14 18 11 13 9 21 16 22 8 25 17 23 15 20 30 24 19 28 29 26 27 31
1 2 3 14 4 16 5 6 8 10 19 11 9 7 17 15 21 12 26 13 24 22 20 27 31 18 25 23 28 29 30
1 2 3 8 5 7 6 4 10 9 12 11 15 18 17 13 14 19 23 16 21 22 20 30 25 24 26 29 27 28 31
1 3 2 8 5 7 6 4 10 9 12 11 15 18 17 13 14 19 23 16 21 22 20 30 25 24 26 29 27 28 31
1 3 2 4 7 8 5 10 11 17 9 19 12 15 13 18 6 14 22 25 16 20 21 26 29 27 28 24 23 30 31
1 3 2 4 7 8 5 10 11 18 9 20 12 15 13 17 6 14 23 25 16 19 21 26 29 27 28 24 22 30 31
1 4 3 2 7 10 5 11 8 15 9 13 12 16 17 20 6 14 19 21 18 24 23 26 28 25 27 29 22 30 31
1 2 4 7 3 16 5 6 8 13 15 9 10 12 19 17 14 11 25 18 23 22 20 29 24 21 26 30 27 28 31
1 2 4 14 3 15 5 6 8 13 16 9 7 11 19 18 12 10 25 17 21 23 24 30 22 20 26 29 27 28 31
5 7 3 1 4 6 9 10 8 2 11 12 14 13 16 18 19 21 15 22 20 17 23 26 24 27 25 30 29 28 31
5 7 3 1 4 6 10 9 8 2 11 12 15 13 16 18 19 21 14 22 20 17 23 26 24 28 25 30 29 27 31
1 5 2 3 4 6 8 11 7 10 16 9 14 12 13 18 20 17 19 15 24 21 22 28 25 23 26 30 29 27 31
2 5 1 7 4 3 10 14 6 9 13 8 18 20 11 16 17 19 15 12 22 21 23 28 27 24 25 31 30 26 29
1 5 9 7 4 3 8 6 10 2 13 15 11 12 16 14 22 21 17 19 18 20 26 27 24 23 28 25 29 30 31
1 6 9 7 4 3 8 5 10 2 13 18 14 11 15 12 22 21 17 19 16 20 26 27 25 23 28 24 29 30 31
1 2 3 11 4 9 6 5 10 8 13 16 14 15 17 21 7 12 23 20 18 19 27 31 24 22 25 29 26 30 28
1 2 4 12 3 10 6 5 9 7 13 16 14 15 17 21 8 11 23 18 20 19 28 31 24 22 25 27 26 29 30
2 4 1 6 7 18 9 3 8 5 11 12 20 15 13 21 10 17 14 23 19 16 24 31 27 25 26 29 22 28 30
2 4 1 5 7 19 9 3 8 6 10 12 20 15 13 21 11 16 14 23 18 17 25 31 27 24 26 29 22 28 30
1 3 5 7 4 11 8 2 9 6 10 12 14 18 19 16 21 20 22 15 17 13 24 28 23 26 25 30 29 27 31
1 2 8 12 4 10 5 3 6 22 7 11 13 16 15 21 19 14 25 26 17 23 24 27 20 9 28 18 29 30 31
1 6 3 4 2 14 10 8 7 5 11 16 22 13 12 15 23 25 19 18 24 9 20 21 31 27 17 29 26 28 30
Country
China
Clinical Review & Education Special Communication Global Burden of Cancer 2015
534 JAMA Oncology April 2017 Volume 3, Number 4 (Reprinted) jamaoncology.com
Copyright 2017 American Medical Association. All rights reserved.
in Table 2, between 2005 and 2015, incidence (95% UI) increased by
37% (32.1%-41.0%) from 1.2 million (1.19-1.24 million) to 1.7 million (1.6-
1.7 million) cases. Most of this increase can be explained by an aging
and growing population, however, even with the same population size
and age structure, colon and rectum cancer cases would have in-
creased by 5% between 2005 and 2015 reflecting a change in age-
specific incidence rates.
Figure 9 shows similar trends in ASIRs between men and women
for all levels of SDI except for the high-middle SDI quintile, where
trends are decreasing in women but increasing in men. As can be seen
in Web Table 1, ASIRs (95% UIs) have increased by 7% (1.8%-11.6%)
between 2005 and 2015 for men but have remained stable for
women at the global level: −0.2% (−4.3% to 4.4%). The largest in-
crease occurred in low-middle SDI countries at 25% (10.3%-
40.2%) for men and 13% (0.7%-27.4%) for women.
Between 2005 and 2015, age-standardized DALY rates for both
sexes decreased by 8% (−10.2% to −6.2%) at the global level, with
the largest decrease in high-SDI countries of 11% (−13.6% to −9.1%)
and the largest (nonsignificant) increase in the low SDI quintile of
9% (−6.0% to 27.8%) (Web Table 3).
4. Prostate Cancer
In 2015, there were 1.6 million (95% UI, 1.3-2.2 million) incident cases
of prostate cancer and 366 000 (95% UI, 303 000-460 000)
deaths. Prostate cancer caused 6.3 million (95% UI, 5.2-7.9 million)
DALYs globally in 2015, with 82% coming from YLLs and 18% from
Figure 6. Cancers Ranked Globally and for Both Sexes by Absolute Years of Life Lost (YLLs)
1 Tracheal, bronchus, and lung cancer 1Tracheal, bronchus, and lung cancer
2 2Liver cancerLiver cancer
3 Stomach cancer 3Stomach cancer
4 4Colon and rectum cancerColon and rectum cancer
5 Breast cancer 5Breast cancer
6 6LeukemiaLeukemia
7 Esophageal cancer 7Esophageal cancer
8 8Pancreatic cancerBrain and nervous system cancer
9 Cervical cancer 9Brain and nervous system cancer
10 10Cervical cancerPancreatic cancer
11 Non-Hodgkin lymphoma 11Non-Hodgkin lymphoma
12 12Prostate cancerAcute lymphoid leukemia
13 Acute myeloid leukemia 13Acute lymphoid leukemia
14 14Acute myeloid leukemiaProstate cancer
15 Ovarian cancer 15Ovarian cancer
16 16Lip and oral cavity cancer Lip and oral cavity cancer 
17 17Bladder cancer
18 Kidney cancer 18Bladder cancer
19 19Gallbladder and biliary tract cancerGallbladder and biliary tract cancer
20 Larynx cancer 20Larynx cancer
21 21Multiple myelomaUterine cancer
22 Nasopharynx cancer 22Uterine cancer
23 23Nasopharynx cancerMultiple myeloma
24 Other pharynx cancer 24Other pharynx cancer
25 25Malignant skin melanomaMalignant skin melanoma
26 Chronic lymphoid leukemia 26Chronic lymphoid leukemia
14.3 (10.8 to 18.9)
4.6 (−1.6 to 15.4)
−6.9 (−10.2 to −3.7)
17.4 (14.8 to 20.2)
17.2 (9.3 to 24.3)
6.2 (2.5 to 9.9)
−7.8 (−12.7 to −2.3)
26.1 (23.2 to 29.0)
13.0 (4.8 to 20.8)
2.3 (−4.4 to 10.8)
22.7 (10.3 to 30.4)
25.9 (22.0 to 29.9)
3.8 (−2.1 to 9.6)
13.1 (7.8 to 18.0)
18.0 (13.1 to 22.9)
27.5 (23.4 to 32.2)
24.6 (19.7 to 29.0)
17.9 (14.3 to 21.6)
6.7 (2.1 to 11.4)
9.6 (6.3 to 13.2)
27.9 (22.8 to 32.5)
4.5 (−2.2 to 12.6)
5.5 (−2.5 to 12.0)
20.4 (14.7 to 25.9)
19.1 (12.6 to 23.9)
5.5 (−0.1 to 11.1)
−9.4 (−13.3 to −4.9)
−12.1 (−16.2 to −7.9)
28.6 (24.1 to 33.2)
18.7 (8.3 to 24.8)
5.0 (−1.9 to 11.19)
−11.5 (−14.2 to −8.0)
−16.9 (−21.6 to −8.8)
−27.3 (−29.8 to −24.7)
−8.9 (−10.8 to −6.8)
−7.5 (−13.5 to −2.2)
−8.0 (−11.1 to −4.9)
−28.7 (−32.5 to −24.5)
−2.8 (−4.9 to −0.6)
−5.3 (−11.8 to 1.1)
−18.6 (−24.0 to −12.0)
0.3 (−9.4 to 6.0)
−4.2 (−7.1 to −1.3)
−6.4 (−11.5 to −1.3)
−3.1 (−7.4 to 0.9)
−7.5 (−11.3 to −3.9)
−0.2 (−3.5 to 3.4)
−1.5 (−4.9 to 2.0)
−17.6 (−21.2 to −13.9)
−15.1 (−17.6 to −12.3)
−9.6 (−12.3 to −6.8)
−1.0 (−4.8 to 2.3)
−18.8 (−24.0 to −12.6)
14.6 (−20.9 to −9.4)
−6.7 (−11.0 to −2.4)
−5.0 (−10.1 to −1.2)
−15.4 (−19.7 to −11.1)
−25.4 (−28.5 to −21.9)
−25.7 (−29.3 to −22.1)
1.9 (−1.6 to 5.3)
−7.1 (−15.0 to −2.3)
−8.6 (−14.7 to −3.4)
27 Chronic myeloid leukemia 27Chronic myeloid leukemia
28 Hodgkin lymphoma 28Hodgkin lymphoma
29 Thyroid cancer 29Mesothelioma
30 Mesothelioma 30Thyroid cancer
31 Testicular cancer 31Testicular cancer
Kidney cancer 




Rate, % (95% CI) 
2005 2015
Rank increased No change Rank decreased
Illustrated data include the percentage change in absolute YLLs (A-YLLs) and
the percentage change in the age-standardized YLL (AS-YLL) rate between
2005 and 2015;. The “other cancers” group is not included in these data
because it contains multiple different types of cancers. Solid lines connecting
the 2005 and 2015 charts indicate increased or unchanged rank for the
connected cancers; dotted lines indicate decreased rank.
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YLDs (eFigure 13 in the Supplement). The odds of developing pros-
tate cancer between ages 0 to 79 years was 1 in 14 at the global level
and ranged from 1 in 47 men for low-middle SDI countries to 1 in 6
men in high SDI countries (eTable 16 in the Supplement).































































1990 1995 2000 2005 2010 2015
Male casesB
0
The y-axes differ in scale between male and female graphs to reflect differing incidence rates between sexes. The colored section of the higher-scale y-axis
represents the entirety of the lower-scale y-axis.





























































The y-axes differ in scale between
male and female graphs to reflect
differing incidence rates between
sexes. The colored section of the
higher-scale y-axis represents the
entirety of the lower-scale y-axis.


























































The y-axes differ in scale between male and female graphs to reflect differing incidence rates between sexes. The colored section of the higher-scale y-axis
represents the entirety of the lower-scale y-axis.
Global Burden of Cancer 2015 Special Communication Clinical Review & Education
jamaoncology.com (Reprinted) JAMA Oncology April 2017 Volume 3, Number 4 537
Copyright 2017 American Medical Association. All rights reserved.
ASIRs and ASDRs (95% UIs) for prostate cancer in 2015 were
the lowest in South Asia: ASIR 11.5 (8.1-17.5), ASDR 7.2 (5.4-9.1); East
Asia: ASIR 12.1 (8.6-16.9), ASDR 6.6 (5.0-8.5); and Central Sub-
Saharan Africa: ASIR 20.5 (12.7-29.8), ASDR 17.6 (11.1-25.1). They were
the highest in Australasia: ASIR 243.9 (162.6-336.6), ASDR 24.1 (17.3-
31.8); high-income North America: ASIR 158.6 (126.0-250.6), ASDR
17.7 (14.4-27.4), and Western Europe: ASIR 151.0 (114.2-230.5), ASDR
20.8 (16.3-30.4) (Web Tables 1 and 2).
In 2015, prostate cancer was the cancer with the highest inci-
dence for men in 103 countries or territories, and the leading cause
of cancer deaths for men in 29 countries (eFigures 9 and 11 in the
Supplement).
Prostate cancer ranked 14th in 2005 and 12th in 2015 for cancer
YLLs (Figure 6) with an increase of 26% (95% UI, 22.0%-29.9%) in
absolute YLLs between 2005 and 2015. As summarized in Table 2, the
increasing incidence rates, together with an aging and growing popu-
lation, have led to a 66% increase in prostate cancer cases since 2005
(974 000 in 2005, 1.6 million in 2015). Thirty-four percent of this in-
crease can be attributed to a change in the age-specific rates.
Prostate cancer ASIRs (95% UIs) for men were the lowest in low-
middle SDI countries (17.6; 12.9-22.5) and the highest in high SDI
countries (123.6; 92.6-181.7). ASIRs have been increasing in all SDI
quintiles between 1990 and 2015, with the largest increase in the
high-SDI countries (Figure 10). Age-standardized DALY rates (95%
UIs) in men were the highest in low SDI countries (368.2; 249.3-
476.1) and the second highest in high SDI countries (302.4; 231.0-
432.0) (Web Table 3).
5. Stomach Cancer
In 2015, there were 1.3 million (1.2-1.4 million) incident cases of stom-
ach cancer and 819 000 (95% UI, 795 000-844 000) deaths world-
wide. Stomach cancer caused 17.4 million (95% UI, 16.9-18 million)
DALYs in 2015 with 98% coming from YLLs and 2% coming from
YLDs (eFigure 13 in the Supplement). One in 27 men and 1 in 68
women develop stomach cancer before age 79 years. The highest
odds for men occurred in middle SDI countries (1 in 25), whereas the
lowest occurred in low-middle SDI countries (1 in 48). For women,
the highest odds were in low SDI countries (1 in 58) and the lowest
in low-middle SDI countries (1 in 83) (eTable 16 in the Supplement).
Globally and for high SDI countries, stomach cancer ranked fifth for
cancer incidence and third for cancer deaths in 2015 (Figures 4 and
5). In high-middle, middle, low-middle, and low SDI countries, stom-
ach cancer ranked third for incidence. For cancer mortality in high-
middle, middle, and low SDI countries, stomach cancer ranked third.
For low-middle SDI countries it ranked second for cancer mortality.
ASIRs and ASDRs (95% UIs) for men in 2015 were lowest in high-
income North America: ASIR 11.7 (10.5-13.0), ASDR 5.2 (5.0-5.4); South
Asia: ASIR 12.8 (10.9-14.9), ASDR 8.4 (7.8-9.1); and Australasia: ASIR 15.1
(12.9-18.1), ASDR 7.0 (6.5-7.5), as summarized in Web Tables 1 and 2.
They were the highest in high-income Asia Pacific: ASIR 90.1 (83.5-
96.9), ASDR 28.5 (27.5-29.5); East Asia: ASIR 46.2 (38.8-56.5), ASDR
33.5 (31.2-36.0); and Central Asia: ASIR 34.9 (32.6-37.2), ASDR 23.6
(22.2-25.0). For women, rates were the lowest in high-income North
America: ASIR 6.1 (5.4-6.8), ASDR 2.9 (2.8-3.0); South Asia: ASIR 6.2
(5.1-7.4), ASDR 4.1 (3.7-4.5); and Southern Sub-Saharan Africa: ASIR 7.5
(6.2-8.8), ASDR 5.3 (4.6-6.2). They were the highest in high-income
Asia Pacific: ASIR 31.5 (28.9-34.2), ASDR 10.6 (10.2-11.1); Andean Latin
America: ASIR 20.9 (18.1-23.7), ASDR 15.2 (13.4-17.3); and East Asia ASIR
18.0 (15.0-21.3), ASDR 13.3 (12.3-14.2).
Stomach cancer was highest in absolute incidence in 2015 for
men in 26 countries and territories and was the leading cause of can-
cer deaths in 11 countries (eFigures 9 and 11 in the Supplement). For
women it was the leading cause of cancer deaths in 4 countries
(eFigure 12 in the Supplement).
Stomach cancer has remained the third highest cause for crude
cancer YLLs between 2005 and 2015, with a 7% decrease in abso-
lute YLLs due to stomach cancer (Figure 6). If the population age
structure and size had remained the same in 2015 as it was in 2005,
incidence would have dropped by 21% due to decreasing rates
(Table 2). ASIRs have dropped substantially since 1990 at the global
level and for all SDI quintiles except the low SDI quintile (Figure 11).
Between 2005 and 2015, age-standardized DALYs for both sexes
decreased by 27% (95% UI, −29.4% to −24.5%) globally, with the
largest decrease in high-middle SDI countries of 32% (95% UI,
−35.8% to −27.5%) (Web Table 3).
6. Liver Cancer
In 2015, there were 854 000 (95% UI, 768 000-961 000) inci-
dent cases for liver cancer globally and 810 000 (750 000-
863 000) deaths. Liver cancer caused 20.6 million (19-22 million)
DALYs in 2015 with 99% coming from YLLs and 1% coming from
YLDs (eFigure 13 in the Supplement). Liver cancer was more com-
mon in men, with 1 in 45 men developing liver cancer before age 79
years compared with 1 in 113 women at the global level. The highest
odds of developing liver cancer was in middle SDI countries, with 1
in 38 men and 1 in 96 women developing liver cancer, whereas the
lowest odds were seen in low-middle SDI countries, with 1 in 98 men
and 1 in 144 women developing liver cancer during their lifetime
(eTable 16 in the Supplement). Globally, liver cancer ranked sixth for
cancer incidence and fourth for cancer deaths in 2015, as shown in
Figures 4 and 5. In low SDI countries, it ranked fourth for cancer in-
cidence and first for cancer mortality, whereas in middle and high-
middle SDI countries it ranked fourth and sixth, respectively, for can-
cer incidence but second for cancer mortality.
ASIRs (95% UIs) (per 100 000 person-years) were the highest
in middle SDI countries in 2015 (15.6; 13.2-18.8), followed by low SDI
countries (14.5; 11.5-17.1), high-middle (13.7; 11.6-16.3), high (11.7; 10.8-
12.7), and low-middle SDI countries (7.1; 6.2-8.3). ASDRs in 2015 for
both sexes were the highest in the low SDI quintile (16.6; 13.2-19.7),
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followed by middle SDI countries (15.8; 14.5-17.5), high-middle SDI
countries (14.5; 12.9-15.8), high SDI countries (7.9; 7.6-8.2), and low-
middle SDI countries (7.5; 6.7-8.7) (Web Tables 1 and 2).
In 2015, ASIRs and ASDRs (95% UIs) for men were the lowest
in South Asia: ASIR 4.7 (3.8-6.2), ASDR 5.1 (4.5-5.9); Southern Latin
America: ASIR 6.1 (5.4-7.3), ASDR 6.8 (6.2-7.5); and Tropical Latin
America: ASIR 6.5 (5.5-8.2), ASDR 7.4 (6.6-8.2). They were the high-
est in high-income Asia Pacific: ASIR 40.1 (34.4-48.3), ASDR 23.8
(22.5-25.2); East Asia: ASIR 36.4 (28.6-48.0), ASDR 39.3 (35.4-
44.1); and Central Sub-Saharan Africa: ASIR 24.4 (13.4-42.7), ASDR
29.4 (15.9-50.3). For women, rates were the lowest in South Asia:
ASIR 3.2 (2.4-4.5), ASDR 3.1 (2.6-3.6); Australasia: ASIR 3.6 (2.4-
6.2), ASDR 2.3 (2.0-2.6); and Southern Latin America: ASIR 4.0 (3.3-
5.2), ASDR 3.9 (3.5-4.3) and the highest in high-income Asia Pa-
cific: ASIR 14.2 (10.9-19.6), ASDR 7.4 (7.0-7.8); East Asia: ASIR 12.5
(9.0-18.2), ASDR 12.1 (10.3-14.1); and Western Sub-Saharan Africa:
ASIR 10.9 (7.0-15.8), ASDR 10.9 (7.0-15.8) (Web Tables 1 and 2).
Liver cancer was the most commonly diagnosed cancer in 2015
for men in 11 countries (eFigure 9 in the Supplement) and the most
common cause of cancer deaths in 40 countries (eFigure 11 in the
Supplement). Liver cancer was the most commonly diagnosed can-
cer for women in Mongolia (eFigure 10 in the Supplement) in 2015
and the leading cause of cancer deaths for women in 5 countries in
2015 (eFigure 12 in the Supplement).
Liver cancer remained the second leading cause of cancer YLLs
between 2005 and 2015 (Figure 6). Aging and population growth
were the drivers of the increase from 709 000 (616 000-782 000)
cases in 2005 to 854 000 (768 000-961 000) cases in 2015, as sum-
marized in Table 2. If the population age structure and size had re-
mained the same in 2015 as they were in 2005, 8% fewer cases of
liver cancer would have been diagnosed in 2015 than in 2005. Glob-
ally, ASIRs slowly decreased since the late 1990s (Figure 12). This
global trend, however, masks an increase in low and high SDI coun-
tries since 1990. ASIRs have been increasing for low SDI countries
since 1990; in high SDI countries, rates decreased until the early
2000s for men and the late 2000s for women and then increased.
Between 2005 and 2015, age-standardized DALY rates for liver can-
cer decreased for both sexes by 17% (95% UI, −21.4% to −8.7%) at
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the global level, with the largest decrease in high-middle SDI coun-
tries of 24% (95% UI, −30.6% to −11.3%) (Web Table 3).
7. Non-Hodgkin Lymphoma
In 2015, there were 666 000 (95% UI, 584 000-710 000) incident
cases of NHL and 231 000 (95% UI, 196 000-244 000) deaths. Non-
Hodgkin lymphoma caused 6.3 million (95% UI, 5.4-6.6 million) DALYs
in 2015, with 95% coming from YLLs and 5% from YLDs (eFigure 13
in the Supplement). One in 78 men and 1 in 110 women at the global
level developed NHL between birth and age 79 years. The highest odds
for developing NHL were in high SDI countries with 1 in 44 men and 1
in 63 women developing NHL. The lowest odds occurred in low SDI
countries, with 1 in 148 men and 1 in 190 women developing NHL.
Globally, for both sexes combined in 2015, NHL ranked sev-
enth for cancer incidence and 11th for cancer deaths (Figures 4 and
5). The highest rank for the incidence of NHL was in low SDI coun-
tries, where it was fifth. However, NHL cancer in low SDI countries
ranked only 11th for death.
Web Tables 1 and 2 illustrate that incidence and death rates in
2015 for men were the lowest in Central Sub-Saharan Africa: ASIR
5.5 (3.4-8.9), ASDR 3.4 (2.1-5.5); Oceania: ASIR 5.8 (4.1-9.7), ASDR
3.0 (2.1-4.7); and South Asia: ASIR 6.0 (4.7-7.4), ASDR 2.9 (2.4-3.2).
They were the highest in high-income North America: ASIR 28.5
(24.2-35.0), ASDR 7.7 (6.3-8.9); Australasia: ASIR 25.3 (20.4-31.4),
ASDR 6.9 (5.4-8.1); and Western Europe: ASIR 20.0 (15.9-23.0), ASDR
5.7 (4.3-6.3). For women, incidence rates in 2015 were the lowest
in Central Asia: ASIR 4.1 (3.4-4.6), ASDR 1.5 (1.3-1.6); North Africa and
Middle East: ASIR 4.4 (3.8-5.5), ASDR 2.0 (1.8-2.6); and South Asia:
ASIR 4.4 (3.0-5.8), ASDR 2.1 (1.6-2.4). They were the highest in
high-income North America: ASIR 20.1 (17.4-26.6), ASDR 5.0 (4.6-
6.1); Australasia: ASIR 18.8 (15.5-24.1), ASDR 4.7 (4.0-5.5); and West-
ern Europe: ASIR 13.7 (11.7-15.9), ASDR 3.6 (2.9-4.0).
Non-Hodgkin lymphoma ranked 11th for cancer YLLs in 2005 and
in 2015 (Figure 6). Cases of NHL increased by 56% between 2005 and
2015 (Table 2). Population growth and population aging would have
increased incidence by 13% each. Rising age-specific incidence rates
with stable population size and structure between 2005 and 2015
would have increased cases by 29%. Figure 13 shows the slight in-
crease in ASIRs between 1990 and 2015 graphically with very similar
trends for men and women and all SDI quintiles. On the global level,
ASIRs per 100 000 person-years (95% UI) for both sexes for NHL have
increased by 23% (13.1%-29.4%) between 2005 and 2015, from 8.0
(7.2-8.5) to 9.8 (8.5-10.4), with the largest increase in middle SDI coun-
tries: 33% (11.3%-52.1%) (Web Table 1). During this timeframe, age-
standardized DALY rates (95% UIs) for both sexes increased at the
global level (1.3% increase; −8.5% to 7.0%), although this increase was
not statistically significant. Large, but not significant decreases of 6%
(−10.2% to 0.1%) occurred in high SDI countries, and the largest, but
also nonsignificant, increase occurred in low-middle SDI countries (7%;
−9.4% to 17.9%) (Web Table 3).
8. Leukemia
In 2015 there were 606 000 (95% UI, 573 000-643 000) new cases
of leukemia worldwide and 353 000 (95% UI, 345 000-363 000)
deaths. In 2015, leukemia caused 12.0 million (95% UI, 11.6-12.5 mil-
lion) DALYs globally, with 97% coming from YLLs and 3% from YLDs
(eFigure 13 in the Supplement). One in 87 men compared with 1 in 137
women developed leukemia between ages 0 and 79 years at the global
level. The highest odds were seen in the high SDI quintile, with 1 in 64
men and 1 in 116 women developing leukemia. The lowest odds
occurred in low SDI countries, with 1 in 124 men and 1 in 164 women
developing leukemia (eTable 16 in the Supplement).
Leukemia ranked eighth for cancer incidence and ninth for can-
cer deaths at the global level in 2015 (Figures 4 and 5). Leukemia in-
cidence was ranked highest for low-SDI and low-middle SDI countries
at sixth place (leukemia was ninth and eighth for cancer deaths in low-
SDI and low-middle SDI countries, respectively). Leukemia was ranked
lowest in high-SDI countries at 13th place (eighth for cancer deaths).
In 2015, ASIRs and ASDRs (95% UIs) for men were the lowest in
Eastern Sub-Saharan Africa: ASIR 6.5 (5.0-8.3), ASDR 3.8 (3.1-4.8);
South Asia: ASIR 7.0 (5.8-8.4), ASDR 4.1 (3.8-4.4); and Central Sub-
Saharan Africa: ASIR 7.2 (4.5-10.8), ASDR 4.4 (2.9-6.5). They were the
highest for men in high-income North America: ASIR 17.1 (15.6-18.9),
ASDR 8.9 (8.5-9.4); Australasia: ASIR 16.1 (12.6-21.0), ASDR 8.8 (7.7-
10.0); and Western Europe: ASIR 14.9 (13.7-16.5), ASDR 8.6 (8.2-9.1).
For women, they were the lowest in Eastern Sub-Saharan Africa: ASIR
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4.6 (3.3-6.2), ASDR 2.7 (2.1-3.5); South Asia: ASIR 4.7 (3.8-5.8), ASDR
2.8 (2.6-3.1); and Western Sub-Saharan Africa: ASIR 5.5 (4.1-7.8), ASDR
3.2 (2.5-4.3). Rates were the highest in high-income North America:
ASIR 10.0 (8.9-11.2), ASDR 4.9 (4.7-5.2); Southeast Asia: ASIR 9.6 (8.1-
11.2), ASDR 5.6 (4.9-6.3); and North Africa and Middle East: ASIR 8.9
(7.9-10.1), ASDR 5.1 (4.6-5.6) (Web Tables 1 and 2).
Leukemia led incident cases in 2015 for men in 5 countries
(eFigure 9 in the Supplement). It remained the sixth leading cause
of cancer YLLs between 2005 and 2015, with a 6% (95% UI, 2.5%-
9.9%) increase in absolute YLLs and an 8% (95% UI, −11.1% to −4.9%)
decrease in age-standardized YLLs (Figure 6).
Between 2005 and 2015, incident cases at the global level in-
creased from 481 000 (95% UI, 456 000-512 000) to 606 000
(95% UI, 573 000-643 000) (total increase of 26% (95% UI, 19.6%-
33.2%); population growth and aging were the drivers behind this
increase. Had the population growth and age-specific rates re-
mained the same as in 2005, there would be only 3% more cases
of leukemia in 2015 (Table 2). Increasing trends in ASIRs are similar
for all SDI quintiles except for countries in the high-middle SDI group,
where rates have decreased since the 2000s (Figure 14).
Between 2005 and 2015, age-standardized DALY rates (95% UIs)
for both sexes decreased by 8% (−10.8% to −4.6%) at the global level,
with the largest decrease in high-middle SDI countries at 12% (−16.6%
to −8.6%), and the largest increase in low SDI countries at 9% (−3.9
to 22.8), although this increase was not significant (Web Table 3).
9. Bladder Cancer
In 2015, there were 541 000 (95% UI, 517 000-567 000) incident
cases for bladder cancer globally and 188 000 (95% UI, 183 000-
193 000) deaths. Bladder cancer caused 3.4 million (95% UI, 3.3-
3.5 million) DALYs in 2015, with 92% coming from YLLs and 8% from
YLDs (eFigure 13 in the Supplement). Bladder cancer was more com-
mon in men, with 1 in 59 men being diagnosed before age 79 years
compared with 1 in 239 women. The odds of developing bladder can-
cer during a lifetime were the highest in high-SDI countries (1 in 36
men and 1 in 165 women) and the lowest in low-SDI countries (1 in
122 men and 1 in 310 women) (eTable 16 in the Supplement). Glob-
ally, bladder cancer ranked ninth for cancer incidence and 13th for
cancer deaths in 2015, as shown in Figures 4 and 5. It ranked the high-
est in high-SDI countries at position 8 (11th for mortality).
In 2015, ASIRs and ASDRs (95% UIs) for men were the lowest
in Oceania: ASIR 4.5 (3.6-5.8), ASDR 2.3 (1.9-2.9); Andean Latin
America: ASIR 5.8 (4.7-7.2), ASDR 2.1 (1.9-2.4); and Central Latin
America: ASIR 5.9 (5.0-6.8), ASDR 2.4 (2.2-2.5). They were the high-
est in high-income North America: ASIR 31.6 (28.5-35.1), ASDR 6.1
(5.8-6.4); Western Europe: ASIR 26.0 (24.1-27.9), ASDR 8.6 (8.1-
9.1); and Central Europe: ASIR 24.1 (21.9-26.6), ASDR 9.4 (8.6-10.1).
For women, incidence rates in 2015 were the lowest in Oceania: ASIR
2.1 (1.6-2.8), ASDR 1.2 (0.9-1.5); Southeast Asia: ASIR 2.2 (1.8-2.7),
ASDR 1.2 (1.0-1.4); and Andean Latin America: ASIR 2.3 (1.8-2.8),
ASDR 1.1 (0.9-1.2). They were the highest in high-income North
America: ASIR 7.7 (6.7-8.8), ASDR 1.8 (1.7-1.9); Western Europe: ASIR
5.7 (5.2-6.3), ASDR 2.0 (1.9-2.2); and Southern Sub-Saharan Africa:
ASIR 5.1 (4.0-6.6), ASDR 2.4 (2.0-2.9) (Web Tables 1 and 2).
Bladder cancer was the most commonly diagnosed cancer in
2015 for men in Egypt (eFigure 9 in the Supplement). Globally, it
dropped from the 17th to the 18th leading cause of cancer YLLs be-
tween 2005 and 2015 (Figure 6). Aging and population growth were
the drivers of the increase: from 413 000 (95% UI, 403 000-
424 000) cases in 2005 to 541 000 (95% UI, 517 000-567 000)
cases in 2015 (Table 2). If population age structure and size had re-
mained the same in 2015 as they were in 2005, bladder cancer in-
cidence would have been stable. However, population growth and
aging led to a 31% increase in incident cases. Worldwide, as well as
in high and high-middle SDI countries, ASIRs peaked in the late 1990s
in both sexes followed by a slow decrease (Figure 15). Rates in-
creased in the low and low-middle quintiles. Between 2005 and
2015, age-standardized DALY rates (95% UIs) for both sexes for blad-
der cancer decreased by 9% (−11.5% to −6.2%) at the global level,
with the largest decrease in high-middle SDI countries by 13%
(−17.0% to −9.7%), and the largest (although nonsignificant) in-
crease in low SDI countries of 3% (−8.8% to 18.2%) (Web Table 3).
10. Cervical Cancer
In 2015, 526 000 (95% UI, 483 000-571 000) women developed
cervical cancer worldwide, and it caused 239 000 (95% UI,
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225 000-252 000) deaths (Table 1). Cervical cancer caused 7 mil-
lion (95% UI, 6.5-7.4 million) DALYs, with 96% coming from YLLs
and 4% from YLDs (eFigure 13 in the Supplement).
One in 68 women developed cervical cancer between birth and
age 79 years at the global level (eTable 16 in the Supplement). The
odds were the highest in low SDI countries, with 1 in 24 women de-
veloping cervical cancer, and the lowest in high SDI countries, where
1 in 115 women developed cervical cancer during a lifetime.
In 2015, ASIRs and ASDRs per 100 000 person-years (95% UIs)
for women were the lowest in Australasia: ASIR 5.6 (4.8-6.5), ASDR
2.4 (2.2-2.7); North Africa and Middle East: ASIR 7.5 (5.8-9.3), ASDR
3.3 (2.8-3.9); and high-income North America: ASIR 7.6 (6.7-8.6), ASDR
2.9 (2.8-3.1); and the highest in Central Sub-Saharan Africa: ASIR 47.4
(25.9-82.4), ASDR 24.7 (13.8-39.9); Southern Sub-Saharan Africa: ASIR
46.8 (35.0-62.3), ASDR 27.0 (21.7-34.0); and Oceania: ASIR 42.3 (22.7-
70.2), ASDR 15.6 (9.2-23.1) (Web Tables 1 and 2).
In 2015, cervical cancer was the most commonly diagnosed can-
cer for women in 11 countries (eFigure 10 in the Supplement) and
the most common cause of cancer deaths for women in 50 coun-
tries (eFigure 12 in the Supplement).
Cervical cancer dropped from the ninth to the tenth leading
cause for cancer YLLs between 2005 and 2015, with a 19% (95%
UI, −25.8% to −12.0%) decrease in age-standardized YLLs (Figure 6).
Total incidence would have decreased by 26% if the population size
and age structure had remained the same as in 2005 due to de-
creasing incidence rates (Table 2). ASIRs decreased globally for all
SDI quintiles (Figure 16). Between 2005 and 2015, age-
standardized DALYs decreased globally in women by 19% (95%
UI, −23.9% to −12.2%) with rates decreasing by 17% to 23% in
low-middle, middle, high-middle, and high SDI countries, but only
by 13% (95% UI, −32.6% to 10.0%) in low SDI countries (Web
Table 3).
Trends in Incidence for Less Common Cancers
Incidence (95% UI) for both sexes increased substantially between
2005 and 2015 for certain cancers, as summarized in Table 2. Thy-
roid cancer cases almost doubled between 2005 and 2015, from
168 000 (160 000-178 000) to 334 000 (310 000-353 000)
cases. Seventy-one percent of this change can be explained by an
increase in age-specific incidence rates (Table 2). At the same time,
the age-standardized YLL rate for thyroid cancer decreased signifi-
cantly by 7% (95% UI, −15.0% to −2.3%) (Figure 6). Melanoma cases
increased from 225 000 (187 000-289 000) in 2005 to 352 000
(282 000-445 000) in 2015, a 56% (95% UI, 48.0%-63.9%) in-
crease. Twenty-eight percent of the change can be explained by an
increase in the age-specific incidence rates (Table 2). Kidney can-
cer cases increased by 53% (95% UI, 45.7%-59.7%) between 2005
and 2015 (from 279 000 (271 000-288 000) to 425 000
(405 000-447 000), with age-specific rates contributing 23% to
this total increase. Mesothelioma has increased from 26 000
(25 000-27 000) to 37 000 (35 000-29 000) cases between 2005
and 2015, a 40% (33.4%-47.0%) increase, of which 9% can be at-
tributed to a rise in age-specific rates.
Discussion
Between 2005 and 2015, the proportion of deaths from noncommu-
nicable diseases (NCDs) increased from 65% in 2005 to 71% in 2015
at the global level.1 Fourteen percent of all deaths in 2005 were due
to cancer, which increased to 16% in 2015.1 Seven percent of all DALYs
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in 2005 were due to cancer, which increased to 9% in 2015.19 Deaths
due to communicable, maternal, neonatal, and nutritional diseases
decreased from 26% in 2005 to 20% in 2015.1 These numbers are
evidence that NCDs may be a barrier to future development.20 The
international health community has responded to this threat, with
major milestones being the 2011 United Nations political declaration
on NCD prevention and control,21 the World Health Organization Glob-
al Action Plan for the Prevention and Control of NCDs 2013-2020,22
and the integration of NCDs in the Sustainable Development Goals.11
The GBD 2015 study identifies some progress in meeting the
targets of the Sustainable Development Goals.23 Between 2005 and
2015, many countries experienced a decrease in cancer mortality de-
spite increasing incidence rates. Countries with increasing cancer mor-
tality rates were dominantly in Sub-Saharan Africa where, with few
exceptions, the complex health care infrastructure required to treat
cancer is generally lacking.24 Efforts are ongoing to expand the exist-
ing resources in the region to allow for improved cancer care.25-28 Can-
cer prevention efforts may, however, be as important as delivery of
care, given the profile of cancer in low SDI countries where the top 3
leading causes of cancer mortality (liver cancer, cervical cancer, and
stomach cancer) are largely preventable.
Prevention and treatment of chronic hepatitis B and C, which ac-
count for the majority of liver cancer deaths, would reduce the inci-
dence and mortality of liver cancer.29 The World Health Organiza-
tion has adopted a global health sector strategy on viral hepatitis that
features a 2030 target of a 65% reduction in mortality related to hepa-
titis B and C. This is to be achieved by reducing the occurrence of new
chronic hepatitis B and C infections by 90% through increased new-
born hepatitis B immunization coverage, blood and injection safety,
harm reduction, and by an 80% treatment rate for chronic hepatitis
B and C.30 Our results show that trends for liver cancer incidence dif-
fer among the SDI quintiles. ASIRs have been decreasing at the global
level and for most SDI quintiles since at least 2000. However, rates
for high SDI countries have increased since 1990, and rates for low
SDI countries increased in the most recent observations (from 2010
to 2015). These findings are consistent with observations in some high-
income countries, where obesity, diabetes, and hepatitis C are thought
to be major contributors to rising incidence rates.31,32
Human papillomavirus vaccination is universally recommended
by health authorities and is expected to reduce cervical cancer inci-
dence over the next decades if vaccination uptake is successful. In the
meantime, screen and treat approaches that have been shown to re-
duce cervical cancer mortality in high-income countries should be
implemented in regions with a high burden of cervical cancer.33-35 The
stark inequity between high SDI countries where cervical cancer is the
18th leading cause of cancer deaths compared with low SDI coun-
tries where it ranks second (Figure 5) is widely recognized by the in-
ternational community; an emerging political commitment to reduc-
ing this gap will hopefully translate into a decreased burden of cervical
cancer in the most affected countries.36 Our results show that prog-
ress in reducing cervical cancer burden was the slowest in low SDI
countries where the decrease in ASIRs and ASDRs was the lowest; a
12% decrease in ASIR occurred for countries at low SDI compared to
a greater than 14% decrease in all other SDI quintiles, and a 14% de-
crease in ASDR in low SDI compared to the other SDI quintiles, with
decreases in ASDR of greater than 16%.
Stomach cancer rates have been declining globally for decades.37
However, our results demonstrate that this trend has not been uni-
form among the SDI quintiles. ASIRs in the lowest SDI quintile in-
creased throughout the GBD study timeframe (1990 to 2015). In the
highest SDI quintile, rates declined until 2010 but have since in-
creased. One possible explanation is the increasing trend of gastric can-
cer of the cardia in high-income countries owing to risk factors such
as obesity, although the mechanism explaining this association is not
fully understood.37-39 Treatment for Helicobacter pylori infection,
which causes about 78% of all stomach cancers, reduces gastric can-
cer incidence, and the International Agency for Research on Cancer
(IARC) recommends that countries investigate whether population-
basedscreeningandtreatmentprogramsfor Hpylori areindicated.40,41
Despite this recommendation, few countries with high incidence of
stomach cancer have implemented populationwide screening pro-
grams. Although studies have shown reductions in stomach cancer
mortality in screened populations, the target group, onset, and mo-
dality of screening programs remain controversial.37,42-46
Prevention and treatment of carcinogenic infections that lead
to these observed cancer patterns in low SDI countries have the po-
tential to decrease future cancer burden as well as reducing asso-
ciated diseases like cirrhosis in endemic areas.47 In addition, limit-
ing transmission can lead to prevention efforts that are sustained
beyond 1 generation.10
The dominance of infection-related cancers in low SDI countries
is an exceptional pattern compared with the leading causes of can-
cer deaths for countries in higher SDI quintiles, where TBL, colorec-
tal, stomach, liver, and breast cancer lead the rankings. The impor-
tance of tobacco control as a crucial cancer control strategy should
therefore not be underestimated, especially since tobacco control has
health benefits reaching far beyond cancer prevention.48 Effective pri-
mary and secondary prevention strategies are available for colorec-
tal cancer with many risk factors being attributed to “Western
lifestyles.”49 Increased physical exercise, avoidance of processed meat,
alcohol, and tobacco, as well as aspirin use have all been associated
with reduced colorectal cancer incidence.49-52 Multiple modalities for
colorectal screening are known to reduce colorectal mortality in high-
income countries.53,54 Means of implementation in other health care
settings is currently being investigated.55 Primary prevention of breast
cancer, which is the leading cause of cancer incidence, death, and
DALYs in women, should be emphasized. However, even in the set-
ting of populationwide primary prevention efforts, it is estimated that
only between 20% and 50% of breast cancer can be prevented.48,56
Therefore, breast cancer control strategies must also focus on early
detection in addition to effective treatment. Early detection strate-
gies can range from improving breast cancer awareness and clinical
breast examination in basic resource settings to mammography
screening.57 Clearly, cancer control strategies focused on early detec-
tion should also target access to the full spectrum of care including
surgical, medical, and radiation oncology; affordable chemothera-
peutics and supportive drugs; and survivorship support and pallia-
tive and hospice care.58 This is imperative not only for breast cancer
but for comprehensive cancer care in general.
The variation in the leading causes of cancer incidence and mor-
tality between countries documented in the GBD study are remark-
able. The largest ranges in rankings for cancer mortality were found
in cervical cancer, acute lymphoid leukemia, and nasopharynx can-
cer followed by esophageal, lip and oral cavity, gallbladder and bili-
ary tract cancer, and melanoma (eFigure 8 in the Supplement). For
cancer incidence, the largest divergence was seen in esophageal
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cancer, cervical cancer, melanoma, acute lymphoid leukemia, kid-
ney, larynx, and gallbladder and biliary tract cancer (eFigure 7 in the
Supplement). For most of these cancers, the observed pattern can be
explained by known risk factors or by access to care. In acute lym-
phoid leukemia, for example, it is well known that the survival rate for
children differs substantially between countries from around 15% to
over 90%, suggestive of disparities in treatment.59 For nasophar-
ynx cancer it is also well known that incidence differs drastically be-
tween populations; this can in part be explained by early infection with
Epstein-Barr virus as well as by a high intake of salt-preserved food.60
Melanoma is a much more common in populations with lighter skin
types.61 Esophageal cancer is a similar example of widely differing in-
cidence rates attributable to risk factor profiles. Risk factors for esoph-
ageal cancer vary depending on the histologic characteristics of squa-
mous cell carcinoma vs adenocarcinoma. For example, it is postulated
that the diverse incidence of esophageal squamous cell carcinoma,
the dominant histologic type in high-endemic areas, is driven by
chronic cell damage from risk factors like smoking, alcohol consump-
tion, heat damage, and nutritional deficiency.62,63 Risk factors for
esophageal adenocarcinoma, which is increasing in traditionally low-
endemic areas, include a high body mass index, smoking, reflux dis-
ease, and a diet low in fruits and vegetables.64,65
A detailed analysis of the reasons behind the observed varia-
tion in cancer burden goes beyond the scope of this analysis. How-
ever, the cited examples show that the descriptive epidemiology ap-
proach of the GBD study can identify patterns of cancer burden that
can be hypothesis generating. This is especially true when cancer
burden is analyzed in conjunction with nonmalignant diseases that
might share similar risk factors—a potential provided by the com-
prehensive nature of the GBD approach.
Limitations
As in prior GBD studies, our estimates depend on the quality and quan-
tity of the data sources available to inform the estimates. Because of
the lag time for data reporting, estimates for 2015 are mainly based
on data and trends from recent years. For many countries, data sources
for informing cancer burden estimation are still sparse, and the GBD
estimates rely heavily on covariate selection in the models and re-
gional patterns. Only an estimated 38% of deaths worldwide were reg-
istered in 2012.66 Alternative data sources for cancer mortality, such
as verbal autopsy, are substantially less reliable.67 To overcome the
limitation from lack of data sources, the GBD study includes cancer
incidence data from registries in the mortality estimation. Cancer reg-
istration has a long tradition in many countries. However, in regions
where the burden of cancer is expected to grow significantly due to
anticipated population growth and aging, cancer registries often only
cover a small fraction of the population, are of low quality, or do not
exist.68 Compared with almost complete coverage of the population
with high-quality cancer registration in Nordic countries or North
America, less than 10% of the population in South America, Asia, and
Africa are covered by high-quality cancer registries.68 With techno-
logical innovation, including an improved ability to identify and link
different types of data sources, cancer surveillance will hopefully be-
come a routine component of every health care system. Endeavors
like the Global Initiative for Cancer Registry Development (http://gicr
.iarc.fr) play a major role in this task.
Cancer mortality estimates are predominantly based on vital reg-
istration data, cancer registry data, and to a much lesser extent other
data sources. If a large proportion of deaths are miscoded, the re-
distribution of these so-called garbage codes can substantially affect
mortality estimates. Since GBD cancer incidence estimates are based
on mortality estimates, garbage code redistribution directly af-
fects cancer incidence. Misclassification of metastatic sites as pri-
mary cancer sites (eg, liver, lung, brain) is another source of poten-
tial bias, especially in locations with limited diagnostic resources.
Changes in coding practices or coding systems may also have an ef-
fect, even though mapping to the GBD causes list includes adjust-
ments to account for different coding systems.69
Cervical and uterine cancer incidence rates are potentially over-
estimated in the GBD in locations where hysterectomies are com-
mon, since rates are calculated without adjustments for the popu-
lation at risk.
For GBD 2015, we have updated the MI (mortality to incidence)
ratios and used out-of-sample validation of a set of potential models
to choose the most appropriate MI model. However, in young age
groups with sparse data, and in areas where no matching mortality
and incidence data exist (which is the case for most countries in Sub-
Saharan Africa), the MI model is based on the combination of trends
for older age groups as well as covariate selection.
The addition of the leukemia subtypes for the GBD 2015 study is
a necessary step; aggregating “leukemia” into a single entity is appro-
priate from neither a public health nor a clinical perspective. How-
ever, when interpreting the results, it is important to recognize that
those data sources for the MI ratios that determine incidence for leu-
kemia subtypes are mostly from high-income countries. Another ca-
veat is that leukemia subtypes are scaled to sum to the leukemia “par-
ent” cause, which can lead to incidence estimates for leukemia
subtypes that are different than what would be expected based on
the MI ratio alone. Changes in classification of leukemia subtypes over
time can also have an effect on the GBD estimates. With the wider
availability of cancer registry data, including childhood cancer regis-
tries, it is expected that estimates will continue to be adjusted in
future iterations of the GBD.
Conclusions
Despite significant reductions in cancer mortality in many coun-
tries, cancer poses a barrier to future development. Incidence is ex-
pected to increase, straining resources even in countries with ad-
vanced health care systems. An expanding arsenal of cancer
prevention and treatment interventions, together with a political
commitment to address NCDs, offers hope that this threat can be
controlled. The GBD study enables timely tracking of progress to-
ward defined targets.23 Since most cancer prevention efforts have
a much broader impact than just reducing cancer incidence, the abil-
ity of the GBD to put single diseases into the perspective of popu-
lation health is unique and of the utmost importance.
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